From pyrrolidinyl-benzodioxane to pyrrolidinyl-pyridodioxanes, or from unselective antagonism to selective partial agonism at α4β2 nicotinic acetylcholine receptor

Each of the four aromatic –CH= of (S,R)-2-pyrrolidinyl-1,4-benzodioxane [(S,R)-6] and of its epimer at the dioxane stereocenter (S,S)-6, previously reported as α4β2 nAChR ligands, was replaced with nitrogen. The resulting four diastereoisomeric pairs of pyrrolidinyl-pyridodioxanes were studied for t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of medicinal chemistry 2017-01, Vol.125, p.1132-1144
Hauptverfasser: Bolchi, Cristiano, Bavo, Francesco, Gotti, Cecilia, Fumagalli, Laura, Fasoli, Francesca, Binda, Matteo, Mucchietto, Vanessa, Sciaccaluga, Miriam, Plutino, Simona, Fucile, Sergio, Pallavicini, Marco
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1144
container_issue
container_start_page 1132
container_title European journal of medicinal chemistry
container_volume 125
creator Bolchi, Cristiano
Bavo, Francesco
Gotti, Cecilia
Fumagalli, Laura
Fasoli, Francesca
Binda, Matteo
Mucchietto, Vanessa
Sciaccaluga, Miriam
Plutino, Simona
Fucile, Sergio
Pallavicini, Marco
description Each of the four aromatic –CH= of (S,R)-2-pyrrolidinyl-1,4-benzodioxane [(S,R)-6] and of its epimer at the dioxane stereocenter (S,S)-6, previously reported as α4β2 nAChR ligands, was replaced with nitrogen. The resulting four diastereoisomeric pairs of pyrrolidinyl-pyridodioxanes were studied for the nicotinic affinity and activity at α4β2, α3β4 and α7 nAChR subtypes and compared to their common carbaisostere. It turned out that such isosteric substitutions are highly detrimental, but with the important exception of the S,R stereoisomer of the pyrrolidinyl-pyridodioxane with the pyridine nitrogen adjacent to the dioxane and seven atoms distant from the pyrrolidine nitrogen. Indeed, this stereo/regioisomer not only maintained the α4β2 affinity of [(S,R)-6], but also greatly improved in selectivity over the α3β4 and α7 subtypes and, most importantly, exhibited a highly selective α4β2 partial agonism. The finding that [(S,R)-6] is, instead, an unselective α4β2 antagonist indicates that the benzodioxane substructure confers affinity for the α4β2 nAChR binding site, but activation of this receptor subtype needs benzodioxane functionalization under strict steric requirements, such as the previously reported 7-OH substitution or the present isosteric modification. [Display omitted] •(S,R)-2-Pyrrolidinyl-1,4-benzodioxane [(S,R)-6] is an α4β2 and α3β4 nAChR antagonist.•Each of the four aromatic CH of (S,R)-6 and of (S,S)-6 (epimer at dioxane C*) was replaced with N.•Only one [(S,R)-9] of the eight pyridodioxanes maintained the α4β2 affinity of (S,R)-6 and of (S,S)-6.•(S,R)-9 has the pyridine N adjacent to the dioxane and seven atoms distant from the pyrrolidine N.•(S,R)-9 is an α4β2 nAChR partial agonist with no effect on α3β4 nAChR.
doi_str_mv 10.1016/j.ejmech.2016.10.048
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1836735886</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0223523416309102</els_id><sourcerecordid>1836735886</sourcerecordid><originalsourceid>FETCH-LOGICAL-c277t-b43f276db7a054bfb2c169ada78de88f60e9bf05bea12f51ab5ad93e5a0125563</originalsourceid><addsrcrecordid>eNp9UctO3DAUtSpQmdL-QYW87KIZbCdOnE2lChWKhMQG1pYfN8WjJA62BzH8Dx_QfgjfhKNhqNiwsXXPPece3XsQ-krJkhJaH6-WsBrA3CxZrjK0JJX4gBa0qUVRMl7toQVhrCw4K6sD9CnGFSGE14R8RAesEZTwtl2gx9PgBzxtQvC9s27c9IWG8cFb5-_VCDj5t81cOLvrxu_YB9zNE9ZjhB5McneA1ZjUHz-6OMzy__ikQnKqx7umSvjpb_X0j-HRGZ9cfrEykDa9ucmG2T2AgSn58Bntd6qP8OXlP0TXp7-uTn4XF5dn5yc_LwrDmiYVuio71tRWN4rwSneaGVq3yqpGWBCiqwm0uiNcg6Ks41RprmxbAleEMs7r8hB9286dgr9dQ0xycNFA3-dl_TpKKsq6KbkQM7XaUk3wMQbo5BTcoMJGUiLngORKbgOSc0AzmgPKsqMXh7UewL6Kdolkwo8tAfKedw6CjMbBaMC6fI0krXfvOzwD3NurJw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1836735886</pqid></control><display><type>article</type><title>From pyrrolidinyl-benzodioxane to pyrrolidinyl-pyridodioxanes, or from unselective antagonism to selective partial agonism at α4β2 nicotinic acetylcholine receptor</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Bolchi, Cristiano ; Bavo, Francesco ; Gotti, Cecilia ; Fumagalli, Laura ; Fasoli, Francesca ; Binda, Matteo ; Mucchietto, Vanessa ; Sciaccaluga, Miriam ; Plutino, Simona ; Fucile, Sergio ; Pallavicini, Marco</creator><creatorcontrib>Bolchi, Cristiano ; Bavo, Francesco ; Gotti, Cecilia ; Fumagalli, Laura ; Fasoli, Francesca ; Binda, Matteo ; Mucchietto, Vanessa ; Sciaccaluga, Miriam ; Plutino, Simona ; Fucile, Sergio ; Pallavicini, Marco</creatorcontrib><description>Each of the four aromatic –CH= of (S,R)-2-pyrrolidinyl-1,4-benzodioxane [(S,R)-6] and of its epimer at the dioxane stereocenter (S,S)-6, previously reported as α4β2 nAChR ligands, was replaced with nitrogen. The resulting four diastereoisomeric pairs of pyrrolidinyl-pyridodioxanes were studied for the nicotinic affinity and activity at α4β2, α3β4 and α7 nAChR subtypes and compared to their common carbaisostere. It turned out that such isosteric substitutions are highly detrimental, but with the important exception of the S,R stereoisomer of the pyrrolidinyl-pyridodioxane with the pyridine nitrogen adjacent to the dioxane and seven atoms distant from the pyrrolidine nitrogen. Indeed, this stereo/regioisomer not only maintained the α4β2 affinity of [(S,R)-6], but also greatly improved in selectivity over the α3β4 and α7 subtypes and, most importantly, exhibited a highly selective α4β2 partial agonism. The finding that [(S,R)-6] is, instead, an unselective α4β2 antagonist indicates that the benzodioxane substructure confers affinity for the α4β2 nAChR binding site, but activation of this receptor subtype needs benzodioxane functionalization under strict steric requirements, such as the previously reported 7-OH substitution or the present isosteric modification. [Display omitted] •(S,R)-2-Pyrrolidinyl-1,4-benzodioxane [(S,R)-6] is an α4β2 and α3β4 nAChR antagonist.•Each of the four aromatic CH of (S,R)-6 and of (S,S)-6 (epimer at dioxane C*) was replaced with N.•Only one [(S,R)-9] of the eight pyridodioxanes maintained the α4β2 affinity of (S,R)-6 and of (S,S)-6.•(S,R)-9 has the pyridine N adjacent to the dioxane and seven atoms distant from the pyrrolidine N.•(S,R)-9 is an α4β2 nAChR partial agonist with no effect on α3β4 nAChR.</description><identifier>ISSN: 0223-5234</identifier><identifier>EISSN: 1768-3254</identifier><identifier>DOI: 10.1016/j.ejmech.2016.10.048</identifier><identifier>PMID: 27810599</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Antagonism ; Benzene Derivatives - chemistry ; Benzene Derivatives - pharmacology ; Benzodioxane ; Dioxanes - chemistry ; Dioxanes - pharmacology ; Drug Design ; HEK293 Cells ; Humans ; Nicotinic Agonists - chemistry ; Nicotinic Agonists - pharmacology ; Partial agonism ; Pyridodioxane ; Pyrrolidines - chemistry ; Pyrrolidines - pharmacology ; Receptors, Nicotinic - metabolism ; Structure-Activity Relationship ; α3β4 nAChR ; α4β2 nAChR</subject><ispartof>European journal of medicinal chemistry, 2017-01, Vol.125, p.1132-1144</ispartof><rights>2016 Elsevier Masson SAS</rights><rights>Copyright © 2016 Elsevier Masson SAS. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c277t-b43f276db7a054bfb2c169ada78de88f60e9bf05bea12f51ab5ad93e5a0125563</citedby><cites>FETCH-LOGICAL-c277t-b43f276db7a054bfb2c169ada78de88f60e9bf05bea12f51ab5ad93e5a0125563</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0223523416309102$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27810599$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bolchi, Cristiano</creatorcontrib><creatorcontrib>Bavo, Francesco</creatorcontrib><creatorcontrib>Gotti, Cecilia</creatorcontrib><creatorcontrib>Fumagalli, Laura</creatorcontrib><creatorcontrib>Fasoli, Francesca</creatorcontrib><creatorcontrib>Binda, Matteo</creatorcontrib><creatorcontrib>Mucchietto, Vanessa</creatorcontrib><creatorcontrib>Sciaccaluga, Miriam</creatorcontrib><creatorcontrib>Plutino, Simona</creatorcontrib><creatorcontrib>Fucile, Sergio</creatorcontrib><creatorcontrib>Pallavicini, Marco</creatorcontrib><title>From pyrrolidinyl-benzodioxane to pyrrolidinyl-pyridodioxanes, or from unselective antagonism to selective partial agonism at α4β2 nicotinic acetylcholine receptor</title><title>European journal of medicinal chemistry</title><addtitle>Eur J Med Chem</addtitle><description>Each of the four aromatic –CH= of (S,R)-2-pyrrolidinyl-1,4-benzodioxane [(S,R)-6] and of its epimer at the dioxane stereocenter (S,S)-6, previously reported as α4β2 nAChR ligands, was replaced with nitrogen. The resulting four diastereoisomeric pairs of pyrrolidinyl-pyridodioxanes were studied for the nicotinic affinity and activity at α4β2, α3β4 and α7 nAChR subtypes and compared to their common carbaisostere. It turned out that such isosteric substitutions are highly detrimental, but with the important exception of the S,R stereoisomer of the pyrrolidinyl-pyridodioxane with the pyridine nitrogen adjacent to the dioxane and seven atoms distant from the pyrrolidine nitrogen. Indeed, this stereo/regioisomer not only maintained the α4β2 affinity of [(S,R)-6], but also greatly improved in selectivity over the α3β4 and α7 subtypes and, most importantly, exhibited a highly selective α4β2 partial agonism. The finding that [(S,R)-6] is, instead, an unselective α4β2 antagonist indicates that the benzodioxane substructure confers affinity for the α4β2 nAChR binding site, but activation of this receptor subtype needs benzodioxane functionalization under strict steric requirements, such as the previously reported 7-OH substitution or the present isosteric modification. [Display omitted] •(S,R)-2-Pyrrolidinyl-1,4-benzodioxane [(S,R)-6] is an α4β2 and α3β4 nAChR antagonist.•Each of the four aromatic CH of (S,R)-6 and of (S,S)-6 (epimer at dioxane C*) was replaced with N.•Only one [(S,R)-9] of the eight pyridodioxanes maintained the α4β2 affinity of (S,R)-6 and of (S,S)-6.•(S,R)-9 has the pyridine N adjacent to the dioxane and seven atoms distant from the pyrrolidine N.•(S,R)-9 is an α4β2 nAChR partial agonist with no effect on α3β4 nAChR.</description><subject>Antagonism</subject><subject>Benzene Derivatives - chemistry</subject><subject>Benzene Derivatives - pharmacology</subject><subject>Benzodioxane</subject><subject>Dioxanes - chemistry</subject><subject>Dioxanes - pharmacology</subject><subject>Drug Design</subject><subject>HEK293 Cells</subject><subject>Humans</subject><subject>Nicotinic Agonists - chemistry</subject><subject>Nicotinic Agonists - pharmacology</subject><subject>Partial agonism</subject><subject>Pyridodioxane</subject><subject>Pyrrolidines - chemistry</subject><subject>Pyrrolidines - pharmacology</subject><subject>Receptors, Nicotinic - metabolism</subject><subject>Structure-Activity Relationship</subject><subject>α3β4 nAChR</subject><subject>α4β2 nAChR</subject><issn>0223-5234</issn><issn>1768-3254</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UctO3DAUtSpQmdL-QYW87KIZbCdOnE2lChWKhMQG1pYfN8WjJA62BzH8Dx_QfgjfhKNhqNiwsXXPPece3XsQ-krJkhJaH6-WsBrA3CxZrjK0JJX4gBa0qUVRMl7toQVhrCw4K6sD9CnGFSGE14R8RAesEZTwtl2gx9PgBzxtQvC9s27c9IWG8cFb5-_VCDj5t81cOLvrxu_YB9zNE9ZjhB5McneA1ZjUHz-6OMzy__ikQnKqx7umSvjpb_X0j-HRGZ9cfrEykDa9ucmG2T2AgSn58Bntd6qP8OXlP0TXp7-uTn4XF5dn5yc_LwrDmiYVuio71tRWN4rwSneaGVq3yqpGWBCiqwm0uiNcg6Ks41RprmxbAleEMs7r8hB9286dgr9dQ0xycNFA3-dl_TpKKsq6KbkQM7XaUk3wMQbo5BTcoMJGUiLngORKbgOSc0AzmgPKsqMXh7UewL6Kdolkwo8tAfKedw6CjMbBaMC6fI0krXfvOzwD3NurJw</recordid><startdate>20170105</startdate><enddate>20170105</enddate><creator>Bolchi, Cristiano</creator><creator>Bavo, Francesco</creator><creator>Gotti, Cecilia</creator><creator>Fumagalli, Laura</creator><creator>Fasoli, Francesca</creator><creator>Binda, Matteo</creator><creator>Mucchietto, Vanessa</creator><creator>Sciaccaluga, Miriam</creator><creator>Plutino, Simona</creator><creator>Fucile, Sergio</creator><creator>Pallavicini, Marco</creator><general>Elsevier Masson SAS</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170105</creationdate><title>From pyrrolidinyl-benzodioxane to pyrrolidinyl-pyridodioxanes, or from unselective antagonism to selective partial agonism at α4β2 nicotinic acetylcholine receptor</title><author>Bolchi, Cristiano ; Bavo, Francesco ; Gotti, Cecilia ; Fumagalli, Laura ; Fasoli, Francesca ; Binda, Matteo ; Mucchietto, Vanessa ; Sciaccaluga, Miriam ; Plutino, Simona ; Fucile, Sergio ; Pallavicini, Marco</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c277t-b43f276db7a054bfb2c169ada78de88f60e9bf05bea12f51ab5ad93e5a0125563</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Antagonism</topic><topic>Benzene Derivatives - chemistry</topic><topic>Benzene Derivatives - pharmacology</topic><topic>Benzodioxane</topic><topic>Dioxanes - chemistry</topic><topic>Dioxanes - pharmacology</topic><topic>Drug Design</topic><topic>HEK293 Cells</topic><topic>Humans</topic><topic>Nicotinic Agonists - chemistry</topic><topic>Nicotinic Agonists - pharmacology</topic><topic>Partial agonism</topic><topic>Pyridodioxane</topic><topic>Pyrrolidines - chemistry</topic><topic>Pyrrolidines - pharmacology</topic><topic>Receptors, Nicotinic - metabolism</topic><topic>Structure-Activity Relationship</topic><topic>α3β4 nAChR</topic><topic>α4β2 nAChR</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bolchi, Cristiano</creatorcontrib><creatorcontrib>Bavo, Francesco</creatorcontrib><creatorcontrib>Gotti, Cecilia</creatorcontrib><creatorcontrib>Fumagalli, Laura</creatorcontrib><creatorcontrib>Fasoli, Francesca</creatorcontrib><creatorcontrib>Binda, Matteo</creatorcontrib><creatorcontrib>Mucchietto, Vanessa</creatorcontrib><creatorcontrib>Sciaccaluga, Miriam</creatorcontrib><creatorcontrib>Plutino, Simona</creatorcontrib><creatorcontrib>Fucile, Sergio</creatorcontrib><creatorcontrib>Pallavicini, Marco</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bolchi, Cristiano</au><au>Bavo, Francesco</au><au>Gotti, Cecilia</au><au>Fumagalli, Laura</au><au>Fasoli, Francesca</au><au>Binda, Matteo</au><au>Mucchietto, Vanessa</au><au>Sciaccaluga, Miriam</au><au>Plutino, Simona</au><au>Fucile, Sergio</au><au>Pallavicini, Marco</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>From pyrrolidinyl-benzodioxane to pyrrolidinyl-pyridodioxanes, or from unselective antagonism to selective partial agonism at α4β2 nicotinic acetylcholine receptor</atitle><jtitle>European journal of medicinal chemistry</jtitle><addtitle>Eur J Med Chem</addtitle><date>2017-01-05</date><risdate>2017</risdate><volume>125</volume><spage>1132</spage><epage>1144</epage><pages>1132-1144</pages><issn>0223-5234</issn><eissn>1768-3254</eissn><abstract>Each of the four aromatic –CH= of (S,R)-2-pyrrolidinyl-1,4-benzodioxane [(S,R)-6] and of its epimer at the dioxane stereocenter (S,S)-6, previously reported as α4β2 nAChR ligands, was replaced with nitrogen. The resulting four diastereoisomeric pairs of pyrrolidinyl-pyridodioxanes were studied for the nicotinic affinity and activity at α4β2, α3β4 and α7 nAChR subtypes and compared to their common carbaisostere. It turned out that such isosteric substitutions are highly detrimental, but with the important exception of the S,R stereoisomer of the pyrrolidinyl-pyridodioxane with the pyridine nitrogen adjacent to the dioxane and seven atoms distant from the pyrrolidine nitrogen. Indeed, this stereo/regioisomer not only maintained the α4β2 affinity of [(S,R)-6], but also greatly improved in selectivity over the α3β4 and α7 subtypes and, most importantly, exhibited a highly selective α4β2 partial agonism. The finding that [(S,R)-6] is, instead, an unselective α4β2 antagonist indicates that the benzodioxane substructure confers affinity for the α4β2 nAChR binding site, but activation of this receptor subtype needs benzodioxane functionalization under strict steric requirements, such as the previously reported 7-OH substitution or the present isosteric modification. [Display omitted] •(S,R)-2-Pyrrolidinyl-1,4-benzodioxane [(S,R)-6] is an α4β2 and α3β4 nAChR antagonist.•Each of the four aromatic CH of (S,R)-6 and of (S,S)-6 (epimer at dioxane C*) was replaced with N.•Only one [(S,R)-9] of the eight pyridodioxanes maintained the α4β2 affinity of (S,R)-6 and of (S,S)-6.•(S,R)-9 has the pyridine N adjacent to the dioxane and seven atoms distant from the pyrrolidine N.•(S,R)-9 is an α4β2 nAChR partial agonist with no effect on α3β4 nAChR.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>27810599</pmid><doi>10.1016/j.ejmech.2016.10.048</doi><tpages>13</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0223-5234
ispartof European journal of medicinal chemistry, 2017-01, Vol.125, p.1132-1144
issn 0223-5234
1768-3254
language eng
recordid cdi_proquest_miscellaneous_1836735886
source MEDLINE; Elsevier ScienceDirect Journals
subjects Antagonism
Benzene Derivatives - chemistry
Benzene Derivatives - pharmacology
Benzodioxane
Dioxanes - chemistry
Dioxanes - pharmacology
Drug Design
HEK293 Cells
Humans
Nicotinic Agonists - chemistry
Nicotinic Agonists - pharmacology
Partial agonism
Pyridodioxane
Pyrrolidines - chemistry
Pyrrolidines - pharmacology
Receptors, Nicotinic - metabolism
Structure-Activity Relationship
α3β4 nAChR
α4β2 nAChR
title From pyrrolidinyl-benzodioxane to pyrrolidinyl-pyridodioxanes, or from unselective antagonism to selective partial agonism at α4β2 nicotinic acetylcholine receptor
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T12%3A05%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=From%20pyrrolidinyl-benzodioxane%20to%20pyrrolidinyl-pyridodioxanes,%20or%20from%20unselective%20antagonism%20to%20selective%20partial%20agonism%20at%20%CE%B14%CE%B22%20nicotinic%20acetylcholine%20receptor&rft.jtitle=European%20journal%20of%20medicinal%20chemistry&rft.au=Bolchi,%20Cristiano&rft.date=2017-01-05&rft.volume=125&rft.spage=1132&rft.epage=1144&rft.pages=1132-1144&rft.issn=0223-5234&rft.eissn=1768-3254&rft_id=info:doi/10.1016/j.ejmech.2016.10.048&rft_dat=%3Cproquest_cross%3E1836735886%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1836735886&rft_id=info:pmid/27810599&rft_els_id=S0223523416309102&rfr_iscdi=true